Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

The dual role of regulatory T cells in hepatitis B virus infection and related hepatocellular carcinoma
  • +2
  • Jinan He,
  • Rui Miao,
  • Yao Chen,
  • Han Wang,
  • Mei Liu
Jinan He
Huazhong University of Science and Technology Tongji Medical College Tongji Hospital
Author Profile
Rui Miao
Guangzhou Women and Children's Medical Center
Author Profile
Yao Chen
Yunnan Cancer Hospital
Author Profile
Han Wang
Huazhong University of Science and Technology Tongji Medical College Tongji Hospital
Author Profile
Mei Liu
Huazhong University of Science and Technology Tongji Medical College Tongji Hospital

Corresponding Author:[email protected]

Author Profile

Abstract

Hepatocellular carcinoma (HCC) represents a significant global cause of cancer-related mortality. Hepatitis B virus (HBV)infection is a major etiologic factor leading to HCC. While noteworthy progress has been made in managing HBV replication, achieving a cure for HBV-related HCC (HBV-HCC) remains challenging, and the overall survival outcome for HCC remains suboptimal. HBV persistence is attributed to a myriad of mechanisms, encompassing both innate and adaptive immune responses. Regulatory T cells(Tregs) are pivotal in upholding immune tolerance and modulating excessive immune activation. During HBV infection, Tregs mediate specific T cell suppression, thereby contributing to both persistent infection and the mitigation of liver inflammatory responses. Studies have demonstrated an augmented expression of circulating and intrahepatic Tregs in HBV-HCC, which correlates with impaired CD8 + T cells function. Consequently, Tregs play a dual role in the context of HBV infection and the progression of HBV-HCC. In this comprehensive review, we discuss pertinent studies concerning Tregs in HBV infection, HBV-related cirrhosis and HCC. Furthermore, we provide valuable treatment strategies pertinent to liver cancer management.
09 Nov 20231st Revision Received
13 Nov 2023Submission Checks Completed
13 Nov 2023Assigned to Editor
13 Nov 2023Review(s) Completed, Editorial Evaluation Pending
16 Nov 2023Reviewer(s) Assigned